Re: Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations

Journal of the National Cancer Institute

Volumn 103, Issue 16, 2011, Pages 1278-

  Brandi, Giovanni ^a,b   Biasco, Guido ^a,b   Tavolari, Simona ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; GENE PRODUCT; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN NRAS; PROTEIN PIK3CA; SIMVASTATIN; UNCLASSIFIED DRUG;

CANCER CELL CULTURE; CANCER PATIENT; COLORECTAL CANCER; DRUG EFFICACY; DRUG MECHANISM; ERRATUM; GENE MUTATION; HUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS;

EID: 80051960528     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr266     Document Type: Erratum

References (7)

1. Lee J, Lee I, Han B, et al. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations [published online ahead of print March 11, 2010]. J Natl Cancer Inst. 2011;103(8):674-688.
2. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17):1757-1765.
3. Jhawer M, Goel S, Wilson AJ, et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res. 2008;68(6):1953-1961. (Pubitemid 351416582)
4. Sartore-Bianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 2009;69(5):1851-1857.
5. Siena S, Sartore-Bianchi A, Di Nicolantonio F, et al. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst. 2009;101(19):1308-1324.
6. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11(8): 753-762.
7. Irwin ME, Mueller KL, Bohin N, et al. Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib [published online ahead of print]. J Cell Physiol. 2011;226(9):2316-2328.